Analog Devices Inc
Change company Symbol lookup
Select an option...
ADI Analog Devices Inc
BAC Bank of America Corp
CLOV Clover Health Investments Corp
HRL Hormel Foods Corp
DD Dupont De Nemours Inc
PSRU Valiant Eagle Inc
CRM Salesforce.Com Inc
VLYPP Valley National Bancorp
FEMKX Fidelity® Emerging Markets Fund
XPEV Xpeng Inc
Go

Information Technology : Semiconductors & Semiconductor Equipment | Large Cap Blend
Company profile

Analog Devices, Inc. (Analog Devices) designs, manufactures and markets a portfolio of solutions that leverage high-performance analog, mixed-signal and digital signal processing technology, including integrated circuits (ICs), algorithms, software and subsystems. Its products include Analog Products, Converters, Amplifiers/Radio Frequency, Other Analog, Power Management and Reference, and Digital Signal Processing Products. The Company is a supplier of data converter products. The Company is a supplier of high-performance amplifiers. Its analog product line also includes products of high performance radio frequency (RF) ICs. The Company's DSPs are used for high-speed numeric calculations. The Company offers its products for applications in various end markets, such as industrial, automotive, consumer and communications. The Company operates in the United States, Rest of North/South America, Europe, Japan and China.

Postmarket

Last Trade
Delayed
$156.38
2.09 (1.35%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$154.29
Day's Change
-4.30 (-2.71%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
159.41
Day's Low
154.03
Volume
(Below Average)
Volume:
3,016,479

10-day average volume:
3,526,468
3,016,479

TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change

4:43 am ET December 10, 2020 (Globe Newswire) Print

Reportlinker.com announces the release of the report "TNF Alpha Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" - https://www.reportlinker.com/p05995336/?utm_source=GNW

The global TNF alpha inhibitors market is expected to decline from $40.66 billion in 2019 to $39.01 billion in 2020 at a compound annual growth rate (CAGR) of -4.06%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $42.86 billion in 2023 at a CAGR of 3.18%.

The TNF alpha inhibitors market consists of sales of tumor necrosis factor-alpha (TNF-?) inhibitors by entities that manufacture TNF alpha inhibitors. TNF alpha inhibitors are a group of medicines that conquer the body's natural response to TNF, a protein produced by white blood cells, involved in early inflammatory events. These are important treatments in the number of inflammatory conditions including spondylarthritis, psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD).

North America was the largest region in the TNF alpha inhibitors market in 2019. Asia-Pacific is expected to be the fastest-growing region during the forecast period.

In May 2020, AbbVie Inc, a US-based biopharmaceutical company, completed the acquisition of Allergan plc for an amount of $63 billion. The acquisition is expected to expand and diversify AbbVie Inc's revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology.

The TNF alpha inhibitors market covered in this report is segmented by drug into remicade (infliximab); enbrel (etanercept); humira (adalimumab); cimzia (certolizumab pegol); simponi (golimumab). It is also segmented by route of administration into oral; subcutaneous; intravenous; others and by disease type into inflammatory bowel disease; psoriatic arthritis; ulcerative colitis (UC); rheumatoid arthritis; ankylosing spondylitis; others.

The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market.

The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.

Read the full report: https://www.reportlinker.com/p05995336/?utm_source=GNW

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

https://ml.globenewswire.com/media/3e0b82c2-02d7-44c8-b22f-561e0f321f39/small/reportlinker-logo-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.